Otsuka Pharmaceutical’s Fukuroi Factory Receives FY2011 METI Minister Award for Factories Making an Outstanding Contribution to the Environment
Antipsychotic Agent ABILIFY® Receives Regulatory Approvals for Additional Indication "Improvement of Manic Symptoms Associated with Bipolar Disorder" and for New Dosage Form "ABILIFY® OD Tablets"
Otsuka Pharmaceutical Files New Drug Application for The Dopamine Agonist Transdermal Patch, Rotigotine Patch, in Japan
Otsuka Pharmaceutical and UCB focus collaboration in the area of Central Nervous System (CNS) disorders
Mucosta® ophthalmic suspension UD2% releases on January 5, 2012
